The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
SITC 2022 | Key limitations of current treatment options for patients with MSS-CRC
Michael Overman, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses the limitations of treatment options for patients with microsatellite stable colorectal cancer (MSS-CRC). MSS-CRC is a tumor type that is in critical need of novel therapies, including effective immunotherapies. A large number of patients become refractory following standard therapy and many of the therapies used in the refractory setting have very limited activity. This interview took place at the 37th Annual Meeting of the Society for Immunotherapy in Cancer (SITC 2022) in Boston, MA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
